In a Phase 1 clinical trial, PB2452 demonstrated the potential to bring life-saving therapeutic benefit through immediate and sustained reversal of ticagrelor's antiplatelet activity, mitigating concerns regarding bleeding risks associated with the use of antiplatelet drugs
. The Phase 1 clinical trial of PB2452 in healthy volunteers was published in the New England Journal of Medicinein March 2019.1 In April 2019, PB2452 received Breakthrough Therapy designation from the U.S.
About Oral Antiplatelet Therapy Oral Antiplatelet therapy plays an important role in the management of ACS, as Antiplatelet drugs
help prevent platelet aggregation in arterial thrombosis, most prominently in myocardial infarction and ischemic stroke.
While several antiplatelet drugs
fight clots, their effects are not easily reversible, leaving patients vulnerable if they develop unexpected severe bleeding or are in need of an emergency surgical procedure.
The new drug candidates, products of Verseon's computationally driven drug discovery platform, could become the first anticoagulants suitable for long-term co-administration with antiplatelet drugs
for patients with coronary artery disease.
Current practice is to have heart attack patients take antiplatelet drugs
such as aspirin, but these data suggest they also may need blood thinners to prevent clots.
decrease platelet aggregation and prevent thrombus formation.
Drugs targeting arterial thrombi include the antiplatelet drugs
(aspirin, clopidogrel, abciximab, eptifibatide and tirofiban) and the fibrinolytics (streptokinase and alteplase).
If you have a drug-eluting stent (DES), the combination of two common antiplatelet drugs
is lessening the chance that a heart attack-causing blood clot will form inside the stent.
Note, however, that selenium may also interfere with your current medications, such as anticoagulant or antiplatelet drugs
, and birth control pills among others may affect the effectiveness of each drug or medication if taken alongside selenium.
We present a case of gastrointestinal bleeding due to antiplatelet therapy after percutaneous coronary intervention (PCI) and secondary in-stent thrombosis due to discontinuation of antiplatelet drugs
. The experience of treatment of this case may shed some light on antiplatelet therapy in this clinical dilemma for patients with both high bleeding and high ischemia risk.